Bay98-7196, Dose Finding / POC Study

ClinicalTrials.gov ID: NCT02203331

Public ClinicalTrials.gov record NCT02203331. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period

Study identification

NCT ID: NCT02203331
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bayer; Industry
Enrollment: 319 participants

Conditions and interventions

Conditions

Endometriosis

Interventions

Placebo Drug
Levonorgestrel Drug
Anastrozole Drug
Lupron / Leuprolide acetate Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 15, 2014
Primary completion: Oct 23, 2016
Completion: Oct 23, 2016
Last update posted: Nov 6, 2023

2014 – 2016

United States locations

U.S. sites: 25
U.S. states: 15
U.S. cities: 25

Facility	City	State	ZIP	Site status
Not listed	San Diego	California	92108	—
Not listed	San Francisco	California	94158-2509	—
Not listed	Gainesville	Florida	32605	—
Not listed	New Port Richey	Florida	34652	—
Not listed	Atlanta	Georgia	30338	—
Not listed	Sandy Springs	Georgia	30328	—
Not listed	Chicago	Illinois	60611	—
Not listed	Palos Heights	Illinois	60463	—
Not listed	Wichita	Kansas	67226	—
Not listed	Marrero	Louisiana	70072	—
Not listed	Canton	Michigan	48187	—
Not listed	Detroit	Michigan	48034	—
Not listed	Saginaw	Michigan	48604	—
Not listed	Lincoln	Nebraska	68510	—
Not listed	Neptune City	New Jersey	07754	—
Not listed	Plainsboro	New Jersey	08536	—
Not listed	Durham	North Carolina	27713	—
Not listed	Greensboro	North Carolina	27408	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Columbus	Ohio	43213	—
Not listed	Dayton	Ohio	45409	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Chattanooga	Tennessee	37404	—
Not listed	Seattle	Washington	98105	—
Not listed	Madison	Wisconsin	53562	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 92 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02203331, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 6, 2023 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02203331 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →